Selisistat, a SIRT1 inhibitor, enhances paclitaxel activity in luminal and triple-negative breast cancer: in silico, in vitro, and in vivo studies. - Wawruszak, Anna; Luszczki, Jarogniew; Bartuzi, Damian; Kalafut, Joanna; Okon, Estera; Czerwonka, Arkadiusz; Stepulak, Andrzej (Journal of Enzyme Inhibition & Medicinal Chemistry, 2025)